QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文 PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 卷号: 11, 期号: 1 作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/04 Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文 The Patient - Patient-Centered Outcomes Research, 2018, 卷号: 11, 期号: 1, 页码: 131-141 作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11 作者:  Hirsh, V.;  Tan, E.;  Wu, Y.;  Sequist, L.;  Zhou, C. 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/04 dose adjustment  PROs  afatinib   Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials 期刊论文 ANNALS OF ONCOLOGY, 2016, 卷号: 27, 期号: 11 作者:  Zhou, C.;  Yang, J. C. -H.;  Sequist, L. V.;  Schuler, M.;  Geater, S. L. 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/04 afatinib  NSCLC  EGFR  first-line  phase III  dose   Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials 期刊论文 Annals of Oncology, 2016, 卷号: 27, 期号: 11, 页码: 2103-2110 作者:  Yang, J. C. -H.;  Sequist, L. V.;  Zhou, C.;  Schuler, M.;  Geater, S. L. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/03 adverse event  epidermal growth factor receptors  mutation  plasma drug concentration   Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials 期刊论文 LANCET ONCOLOGY, 2015, 卷号: 16, 期号: 2 作者:  Yang, James Chih-Hsin;  Wu, Yi-Long;  Schuler, Martin;  Sebastian, Martin;  Popat, Sanjay 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/04 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma 期刊论文 EUROPEAN RESPIRATORY JOURNAL, 2012, 卷号: 39, 期号: 2 作者:  Girard, N.;  Sima, C. S.;  Jackman, D. M.;  Sequist, L. V.;  Chen, H. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/19 Adenocarcinoma  epidermal growth factor receptor mutations  lung cancer  nomogram  prediction score  tyrosine kinase inhibitor